Vikas Vujjini, MD
Nephrology · Conway, ARNPI 1275989907
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations.
Across 92 payments — averaging $29.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$601
- Travere Therapeutics, Inc.$368
- AstraZeneca$240
- Mallinckrodt Hospital Products Inc.$196
- Medtronic$148
- Baxter Healthcare$142
- plus $1K from 14 others
What the payments were for
- Food & beverage$2,59395%
- Education$1495%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 16 | $601 |
| Travere Therapeutics, Inc. | 17 | $368 |
| AstraZeneca(2 entities) | 9 | $240 |
| Mallinckrodt Hospital Products Inc. | 7 | $196 |
| Medtronic | 1 | $148 |
| Baxter Healthcare | 1 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $115 |
| Novartis | 4 | $110 |
| Outset Medical Inc | 1 | $103 |
| Ardelyx, Inc. | 2 | $100 |
| Fresenius USA Marketing, Inc. | 5 | $97 |
| Bayer | 4 | $90 |
| GSK | 5 | $85 |
| Aurinia Pharma U.S., Inc. | 3 | $85 |
| Vantive US Healthcare LLC | 1 | $72 |
| Vifor Pharma, Inc. | 3 | $65 |
| OPKO Pharmaceuticals, LLC | 3 | $58 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,742 in reported general payments places this provider in the 70th percentile of 85 nephrology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 63 | $44,440 |
| AuryxiaFerric Citrate | 20 | $32,615 |
| KerendiaFinerenone | 26 | $29,917 |
| JardianceEmpagliflozin | 20 | $21,065 |
| RayaldeeCalcifediol | 12 | $16,947 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 49 | $9,922 |
| Sevelamer Carbonate | 30 | $6,540 |
| Calcium Acetate | 50 | $3,688 |
| ClinisolParenteral Amino Acid 15% No.5 | 34 | $2,719 |
| Torsemide | 77 | $1,661 |
| Clonidine | 16 | $826 |
| Nifedipine ErNifedipine | 52 | $569 |
| Losartan Potassium | 57 | $484 |
| Potassium Chloride | 27 | $410 |
| Allopurinol | 46 | $350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $240 | $44,44063 claims |
| BayerKerendia | $90 | $29,91726 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $58 | $16,94712 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $15 | $14922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 85 nephrology providers in Arkansas.
Other nephrology in Conway
- Mary Shaver-LewisConway$10K
- Drew HeipleRussellville$236K
- Luis JuncosLittle Rock$66K
- John HeifnerLittle Rock$45K
- Shaker QaqishNorth Little Rock$16K
- Michael GerschHot Springs$10K
- Clinton EdwardsJonesboro$8K
- Hania Al-ShahrouriFort Smith$8K
- Mashhud MirzaMarion$7K
- John ArthurLittle Rock$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.